Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial
机构：[1]PLA Cancer Center, Jinling Hospital, Nanjing, China[2]Medical Oncology, West ChinaHospital, Sichuan University, Chengdu, China[3]Medical Oncology, Cancer Hospital,Chinese Academy of Medical Sciences, Beijing, China[4]Medical Oncology, XinqiaoHospital, Army Medical University, Chongqing, China[5]Hepatobiliary and PancreaticSurgery, The First Affiliated Hospital, College of Medicine, Hangzhou, China[6]Hepatology,The Sixth People’s Hospital of Shenyang, Shenyang, China[7]Medical Oncology,Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou,China河南省肿瘤医院[8]Medical Oncology, Daping Hospital, Army Medical University, Chongqing,China[9]Intervention and Cell Therapy Center, Peking University Shenzhen Hospital,Shenzhen, China北京大学深圳医院深圳医学信息中心[10]Medical Oncology, General Hospital of Northern Theater Command,Shenyang, China[11]Liver Surgery, Sun Yat-sen University Cancer Center,Guangzhou, China[12]Hepatobiliary and Pancreatic Disease, The First Hospital of JilinUniversity, Changchun, China[13]Department of Tumor Intervention Therapy, HepingBranch, General Hospital of Northern Theater Command, Shenyang, China[14]HepaticOncology, Zhongshan Hospital, Fudan University, Shanghai, China[15]Clinical Operations,Suzhou Zelgen Biopharmaceuticals Co., Ltd, Suzhou, China
第一作者机构：[1]PLA Cancer Center, Jinling Hospital, Nanjing, China
推荐引用方式(GB/T 7714)：
S. Qin,F. Bi,C. Cui,et al.Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial[J].ANNALS OF ONCOLOGY.2020,31:S688-S688.doi:10.1016/j.annonc.2020.08.1098.
APA：
S. Qin,F. Bi,C. Cui,B. Zhu,J.Wu...&X.Wu.(2020).Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial.ANNALS OF ONCOLOGY,31,
MLA：
S. Qin,et al."Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial".ANNALS OF ONCOLOGY 31.(2020):S688-S688
医学